Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

the boots company plc - liquid paraffin - oral liquid - 1ml/1ml

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

lloyds pharmacy ltd - liquid paraffin - oral liquid - 1ml/1ml

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

bell,sons & co (druggists) ltd - liquid paraffin - oral liquid - 1ml/1ml

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

colorama pharmaceuticals ltd - liquid paraffin - oral liquid - 1ml/1ml

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

glaxosmithkline consumer healthcare australia pty ltd - light liquid paraffin -

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

glaxosmithkline consumer healthcare (ireland) limited - benzalkonium chloride; light liquid paraffin; triclosan - bath additive - 52.5%w/w +6.0%w/w +2.0 percent weight/weight - soft paraffin and fat products

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

glaxosmithkline consumer healthcare (ireland) limited - light liquid paraffin - gel - 70 percent weight/weight - soft paraffin and fat products

Estats Units - anglès - NLM (National Library of Medicine)

remedyrepack inc. - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 10 mg - olanzapine tablets are indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6 week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6 week trial [ see clinical studies (14.1) ]. when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [ see warnings and precautions ( 5.5 ) ]. olanzapine tablets are indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and maintenance treatment of bipolar i disorder. efficacy was established in three clinical trials in adult patients with manic or mixed epi

Estats Units - anglès - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 5 mg - olanzapine orally disintegrating tablets are indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6-week trial [see clinical studies (14.1)]. when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions (5.5)]. monotherapy — olanzapine orally disintegrating tablets are indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and maintenance treatment of bipolar i disorder. efficacy was established in three clin

Estats Units - anglès - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 2.5 mg - olanzapine tablets are indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6 week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6 week trial [see clinical studies (14.1) ]. when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions ( 5.5 ) ]. olanzapine tablets are indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and maintenance treatment of bipolar i disorder. efficacy was established in three clinical trials in adult patients with manic or mixed episo